395683-14-4
395683-14-4 structure
- Name: Imrecoxib
- Chemical Name: Imrecoxib
- CAS Number: 395683-14-4
- Molecular Formula: C21H23NO3S
- Molecular Weight: 369.477
- Catalog: Signaling Pathways Immunology/Inflammation COX
- Create Date: 2018-03-18 08:00:00
- Modify Date: 2025-08-24 19:18:44
-
Imrecoxib (BAP-909) is a novel and selective cyclooxygenase 2 (COX-2) inhibitor with an IC50 value of 18 nM, it also inhibits COX1- activity with an IC50 value of 115 nM. Imrecoxib (BAP-909) has anti-inflammatory effect[1].
| Name | Imrecoxib |
|---|---|
| Synonyms |
3-(4-Methylphenyl)-4-[4-(methylsulfonyl)phenyl]-1-propyl-1,5-dihydro-2H-pyrrol-2-one
4-(4-(methylsulfonyl)phenyl)-1-propyl-3-(p-tolyl)-1H-pyrrol-2(5H)-one 2H-Pyrrol-2-one, 1,5-dihydro-3-(4-methylphenyl)-4-[4-(methylsulfonyl)phenyl]-1-propyl- 2H-Pyrrol-2-one,1,5-dihydro-3-(4-methylphenyl)-4-[4-(methylsulfonyl)phenyl]-1-propyl- 4-(4-(methylsulfonyl)phenyl)-1-propyl-3-(p-tolyl)-1,5-dihydro-2H-pyrrol-2-one |
| Description | Imrecoxib (BAP-909) is a novel and selective cyclooxygenase 2 (COX-2) inhibitor with an IC50 value of 18 nM, it also inhibits COX1- activity with an IC50 value of 115 nM. Imrecoxib (BAP-909) has anti-inflammatory effect[1]. |
|---|---|
| Related Catalog | |
| Target |
Human COX-1:115 nM (IC50) Human COX-2:18 nM (IC50) |
| In Vitro | Imrecoxib (BAP-909) (0.1-10 µM; 24 hours) decreases COX-2 mRNA level induced by PMA+LPS at a dose dependent manner in U937 cells[1]. RT-PCR[1] Cell Line: U937 cells Concentration: 0.1 µM; 1 µM; 10 µM Incubation Time: 24 hours Result: Decreased COX-2 mRNA level. |
| In Vivo | Imrecoxib (BAP-909) (gastrointestinal administration; 5-20 mg/kg; 1 hour before carrageenan injection) inhibits carrageenan-induced acute inflammation, and the inhibitory effect is maximal at 4 hours[1]. Imrecoxib (BAP-909) (gastrointestinal administration; 5-20 mg/kg; started on day 7; 26 days) diminishes the secondary paw swelling and inhibits heat-inactivated BCG induced-inflammtory polyarthritis[1]. Animal Model: Rat carrageenan-induced edema model[1] Dosage: 5 mg/kg, 10 mg/kg, 20 mg/kg Administration: Gastrointestinal administration; 5-20 mg/kg; 1 hour before carrageenan injection Result: Inhibited the edema response with different doses. Animal Model: Rat adjuvant-induced arthritis (AIA) model[1] Dosage: 5 mg/kg, 10 mg/kg, 20 mg/kg Administration: Gastrointestinal administration; 5-20 mg/kg; started on day 7; 26 days Result: Inhibited adjuvant-induced chronic inflammation at the doses of 10 and 20 mg/kg. |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 604.1±55.0 °C at 760 mmHg |
| Molecular Formula | C21H23NO3S |
| Molecular Weight | 369.477 |
| Flash Point | 319.1±31.5 °C |
| Exact Mass | 369.139862 |
| PSA | 62.83000 |
| LogP | 3.57 |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.590 |
| Hazard Codes | Xi |
|---|